Comparing Two Treatments for IVIG-Resistant Kawasaki Disease – Evidence Update for Clinicians
Children with resistant KD who received infliximab were more likely to have their fever resolve within 24 hours than were children who received a second dose of IVIG. On average, children who received infliximab also had shorter fever duration, spent less time in the hospital, and were less likely to have a serious treatment-related adverse event such as hemolytic anemia than children who received a second dose of IVIG. The two treatments did not differ significantly in inflammatory markers or coronary artery z-scores.
